Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.

MLA

Sharip, Mohmmed Tauseef, et al. “Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies.” Journal of Clinical Medicine, vol. 13, no. 8, Apr. 2024, p. 2187. EBSCOhost, https://doi.org/10.3390/jcm13082187.

APA

Sharip, M. T., Nishad, N., Pillay, L., Goordoyel, N., Goerge, S., & Subramanian, S. (2024). Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies. Journal of Clinical Medicine, 13(8), 2187. https://doi.org/10.3390/jcm13082187

Chicago

Sharip, Mohmmed Tauseef, Nilanga Nishad, Lushen Pillay, Nilkantsingh Goordoyel, Samuel Goerge, and Sreedhar Subramanian. 2024. “Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies.” Journal of Clinical Medicine 13 (8): 2187. doi:10.3390/jcm13082187.